319 related articles for article (PubMed ID: 8313392)
1. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
4. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
[TBL] [Abstract][Full Text] [Related]
5. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
Bieck PR
Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
[TBL] [Abstract][Full Text] [Related]
6. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of reversible and irreversible MAO inhibitors on renal nerve activity in the anesthetized rat.
Lavian G; Finberg JP; Youdim MB
J Neural Transm Suppl; 1994; 41():107-13. PubMed ID: 7931215
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
[TBL] [Abstract][Full Text] [Related]
9. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical pharmacology of moclobemide. A review of published studies.
Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
[TBL] [Abstract][Full Text] [Related]
11. [The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine].
Andreeva NI; Golovina SM; Faermark MF; Shvarts GIa; Mashkovskiĭ MD
Farmakol Toksikol; 1991; 54(2):38-40. PubMed ID: 1884793
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
Finberg JP
Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
[TBL] [Abstract][Full Text] [Related]
13. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
[TBL] [Abstract][Full Text] [Related]
14. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
Alemany R; Olmos G; García-Sevilla JA
Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
[TBL] [Abstract][Full Text] [Related]
15. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
[TBL] [Abstract][Full Text] [Related]
16. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
[TBL] [Abstract][Full Text] [Related]
17. The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats.
Zajaczkowski W; Górka Z
Pol J Pharmacol; 1993; 45(2):157-66. PubMed ID: 8401768
[TBL] [Abstract][Full Text] [Related]
18. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
Waldmeier PC; Stöcklin K
Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
[TBL] [Abstract][Full Text] [Related]
19. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
20. The cheese effect and new reversible MAO-A inhibitors. Proceedings of the round table of the International Conference on New Directions in Affective Disorders, Jerusalem, April 5-9, 1987.
J Neural Transm Suppl; 1988; 26():1-136. PubMed ID: 3162947
[No Abstract] [Full Text] [Related]
[Next] [New Search]
